These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27917324)

  • 21. Characterizing expanded access and compassionate use programs for experimental drugs.
    Miller JE; Ross JS; Moch KI; Caplan AL
    BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician perspectives on compassionate use in pediatric oncology.
    Moerdler S; Zhang L; Gerasimov E; Zhu C; Wolinsky T; Roth M; Goodman N; Weiser DA
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27545. PubMed ID: 30408307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons from CDER's Quality Management Maturity Pilot Programs.
    Maguire J; Fisher A; Harouaka D; Rakala N; Lundi C; Yambot M; Viehmann A; Stiber N; Gonzalez K; Canida L; Buhse L; Kopcha M
    AAPS J; 2023 Jan; 25(1):14. PubMed ID: 36627496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study.
    Borysowski J; Górski A
    J Med Internet Res; 2021 Oct; 23(10):e26890. PubMed ID: 34709189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded Access and Right To Try Requests: The Community Oncologist's Experience.
    Zettler ME; Jeune-Smith Y; Feinberg BA; Phillips EG; Gajra A
    JCO Oncol Pract; 2021 Nov; 17(11):e1719-e1727. PubMed ID: 33886355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.
    Klopfenstein M; Van Campen LE; Garnett T
    Ther Innov Regul Sci; 2015 May; 49(3):352-358. PubMed ID: 29473010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.
    Mackey TK; Schoenfeld VJ
    BMC Med; 2016 Feb; 14():17. PubMed ID: 26843367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expanded Access in The Netherlands: prescribing unregistered medicine].
    Polak TB; Cucchi DGJ; van Rosmalen J
    Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
    Hordijk M; Vermeulen SF; Bunnik EM
    Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Taking AIM at serious illness: implementing an access to investigational medicines expanded access program.
    Joly MM; Edwards TL; Jerome RN; Mainor A; Bernard GR; Pulley JM
    Front Med (Lausanne); 2023; 10():1287449. PubMed ID: 37877021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases.
    Khan A; Bellio MA; Schulman IH; Levi AD; Longsomboon B; Brooks A; Valasaki K; DiFede DL; Pujol MV; Yavagal DR; Bates KE; Si MS; Kaushal S; Green BA; Anderson KD; Guest JD; Burks SS; Silvera R; Santamaria AJ; Lalwani A; Dietrich WD; Hare JM
    Front Cell Dev Biol; 2021; 9():675738. PubMed ID: 34169074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.
    Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA; Darrow JJ
    Front Pharmacol; 2022; 13():913567. PubMed ID: 35677436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try.
    Chapman CR; Belli HM; Leach D; Shah LD; Bateman-House A
    Med Access Point Care; 2021; 5():23992026211005991. PubMed ID: 36204503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications.
    Bunnik EM; Aarts N; van de Vathorst S
    J Pharm Policy Pract; 2017; 10():10. PubMed ID: 28239479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should patients in need be given access to experimental drugs?
    Caplan AL; Bateman-House A
    Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National landscape assessment of academic medical center support for expanded access to investigational products.
    Gravelin M; Adamo JE; Ellison S; Segear E; Parrish AB; Deeter C; Hamill J; Rigan L; Mashour GA; Weatherwax KJ
    J Clin Transl Sci; 2023; 7(1):e4. PubMed ID: 36755539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.